Good evening :)
$
₹
Legend Biotech Corp

Legend Biotech Corp

LEGN

NASDAQ
Asset Logo

Legend Biotech Corp

LEGN

NASDAQ
$23.362.62% (+0.59)
$
₹
$23.362.62% (+0.59)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $4.2B the stock is ranked 1621

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.33
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.53
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-7.2%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 13 analysts reports

Buy
8 analysts
Hold
5 analysts
Sell
0 analyst

Price Upside

+100.36%

Earnings Growth

+99.38%

Rev. Growth

+39.73%

See Detailed Forecast

Company Profile

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 100.36% growth, versus a trailing 3-year CAGR of -29.83%.

2026
Current$22.77Baseline
Analyst Target - 1 year
Target$45.62+100.36%

All values in $

202220232024202520262027$31.22$42.88$54.53Target+100.36%
2026
Current$22.77Baseline
Analyst Target - 1 year
Target$45.62+100.36%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 39.73% growth, versus a trailing 3-year CAGR of 106.41%.

2025
Current$1.02Baseline
Forecast for Dec 2026
High$1.47+43.22%
Average$1.43+39.73%
Low$1.41+37.23%

All values in $ Billion

2021202220232024202520260.060.110.280.621.02Low+37.23%Average+39.73%High+43.22%
2025
Current$1.02Baseline
Forecast for Dec 2026
High$1.47+43.22%
Average$1.43+39.73%
Low$1.41+37.23%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.6Baseline
Forecast for Dec 2026
High$-0.01+99.38%
Average$-0.01+99.38%
Low$-0.01+99.38%

All values in $

202120222023202420252026-2.12-2.53-2.96-0.96-1.6Low+99.38%Average+99.38%High+99.38%
2025
Current$-1.6Baseline
Forecast for Dec 2026
High$-0.01+99.38%
Average$-0.01+99.38%
Low$-0.01+99.38%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

272.3
-39.6
306.3
-30.8
305.1
-54.3
387.5
33.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue93.99186.52160.20186.52195.05255.05272.33306.37305.1387.5
Net Income-59.79-18.19-125.3226.28-100.91-125.38-39.68-30.81-54.333.2
Net Profit Margin-63.61%-9.75%-78.22%14.09%-51.73%-49.15%-14.57%-10.05%-17.79%8.56%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Legend Biotech Corp -3.33-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare LEGN with any stock or ETF
Compare LEGN with any stock or ETF
Comparing from
LEGN
ABBV
AMGN
Loading...

Frequently asked questions

  1. Legend Biotech Corp (LEGN) share price today is $23.36 as of November 5, 2026 at 8:21 PM IST. The stock touched a day high of $23.46 and a day low of $22.47.

  2. Legend Biotech Corp stock trades on NASDAQ under the ticker symbol LEGN.

  3. Legend Biotech Corp's market capitalization is $4.17B as of November 5, 2026 at 8:21 PM IST.

  4. Legend Biotech Corp's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Legend Biotech Corp's price-to-book (P/B) ratio is 3.33 as of November 5, 2026.

  6. Yes, You can buy Legend Biotech Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Legend Biotech Corp shares in three steps: 1. Search Legend Biotech Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Legend Biotech Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Legend Biotech Corp (LEGN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4279 shares at the current price of $23.36.

Loading...